Lyell Immunopharma, Inc. (NASDAQ:LYEL – Free Report) – Research analysts at HC Wainwright increased their Q1 2025 EPS estimates for Lyell Immunopharma in a report issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will earn ($0.17) per share for the quarter, up from their prior estimate of ($0.20). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.
Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.52). The business had revenue of $0.01 million during the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%.
Lyell Immunopharma Price Performance
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its holdings in Lyell Immunopharma by 312.7% during the 3rd quarter. Barclays PLC now owns 240,615 shares of the company’s stock worth $332,000 after purchasing an additional 182,315 shares during the last quarter. SG Americas Securities LLC raised its holdings in Lyell Immunopharma by 102.8% during the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company’s stock worth $75,000 after purchasing an additional 59,182 shares during the last quarter. Jane Street Group LLC raised its holdings in Lyell Immunopharma by 63.7% during the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company’s stock worth $397,000 after purchasing an additional 111,917 shares during the last quarter. State Street Corp raised its holdings in Lyell Immunopharma by 1.9% during the 3rd quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in Lyell Immunopharma during the 3rd quarter worth approximately $52,000. Institutional investors own 66.05% of the company’s stock.
About Lyell Immunopharma
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
See Also
- Five stocks we like better than Lyell Immunopharma
- How to start investing in penny stocks
- How to Build the Ultimate Everything ETF Portfolio
- With Risk Tolerance, One Size Does Not Fit All
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What is a Low P/E Ratio and What Does it Tell Investors?
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.